Systematic Lp(a) testing after percutaneous coronary intervention (PCI) may improve risk stratification, identify candidates for emerging therapies, and guide implementation of targeted secondary prevention strategies in routine cardiovascular (CV) practice. This was the conclusion of Dr Eva Steinacher, Medical University of Vienna, Austria, and colleagues, following an analysis of data from 5,942 consecutive patients undergoing PCI, to investigate their eligibility for emerging therapies and apheresis.
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
